GlassScriptPhysician profile
Amber Dawn Sperry
NPI 1366086258
$2,415.45
in general payments reported to CMS, 2019-2025
32 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $679 · 2023: $1,177 · 2024: $369 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.71 | 2022-2023 | Xifaxan, Trulance, Uceris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $286.93 | 2023-2025 | Lifevest |
| Abbvie INC. | $273.32 | 2022-2024 | |
| Janssen Biotech, INC. | $218.48 | 2022-2023 | Stelara, Simponi, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $166.58 | 2022-2023 | Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $135.59 | 2023-2024 | Verquvo, Dificid |
| Gilead Sciences, INC. | $123.25 | 2023-2024 | Epclusa |
| Regeneron Healthcare Solutions, INC. | $100.16 | 2022-2023 | Dupixent |
| Genzyme Corporation | $83.81 | 2022-2023 | |
| Qol Medical, LLC | $66.13 | 2023 | Sucraid |
| Evoke Pharma, INC. | $50.37 | 2022 | |
| Ironwood Pharmaceuticals, INC | $50.35 | 2022-2023 | Linzess |
| Novartis Pharmaceuticals Corporation | $47.14 | 2024-2025 | |
| Abbott Laboratories | $39.75 | 2025 | Cardiomems, Triclip |
| Kci USA, INC. | $36.81 | 2023 | Prevena |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.21 | 2024 | Jardiance |
| Ferring Pharmaceuticals INC. | $32.38 | 2023 | Rebyota |
| Atricure, INC. | $24.57 | 2024 | |
| Daiichi Sankyo INC. | $23.15 | 2022 | |
| Cardiva Medical, INC. | $20.63 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boston Scientific Corporation | $20.24 | 2024 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $17.06 | 2025 | Onpattro |
| Shockwave Medical, INC | $17.05 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $17.05 | 2023 | Wegovy |
| W. L. Gore & Associates, INC. | $15.87 | 2023 | Gore Enform Preperitoneal Biomaterial |
| Baxter Healthcare | $15.28 | 2022 | |
| Pfizer INC. | $14.77 | 2023 | |
| Heartflow, INC. | $14.52 | 2024 | |
| Fresenius Kabi USA, LLC | $14.15 | 2023 | Idacio |
| Nestle Healthcare Nutrition INC. | $13.75 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2025 | |
| Cvrx, INC. | $8.82 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Sperry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.